BioSpace News Archive

Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced the appointment of Julie Hambleton, M.D. to the Company’s Board of Directors.

Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that it will report results for the first quarter ended March 31, 2020 and provide a business update after market close on Tuesday, May 5, 2020.

Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for 67Cu-SARTATE™, a therapy for the clinical management of neuroblastoma.

NellOne Therapeutics Inc., the early stage biopharmaceutical company using a talented protein to plot a new future for regenerative medicine, has appointed accomplished leader and entrepreneur William A. Malkes as its new Chief Executive Officer.

Biotricity Inc. (OTCQB : BTCY ), a medical diagnostic and consumer healthcare technology company, announced that its CEO, Waqaas Al-Siddiq, was recently interviewed on Newsmax to discuss Remote Patient Monitoring, Telemedicine and how Biotricity and its Bioflux solution is currently being used to remotely monitor patients. “It is exciting and humbling to have the Company and our technology recognized as a leader. Remote Diagnost

New energy deal puts Boston Scientific on pace to reach goal of carbon neutral manufacturing and operations

Unchained Labs, the life sciences company that’s all about getting biologics researchers the right tool for the job, launched its new Fundamentals UV/Vis standards and performance verification protocols for the Big Lunatic platform

Study examined the safety and tolerability of faster infusion rates and higher infusion volumes, as well as the feasibility of a new manual push administration method [21-April-2020] PHILADELPHIA , April 21, 2020 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that a clinical study examining faster infusion rates and higher volumes than curre

Audentes Therapeutics, Inc., an Astellas genetic medicines company, announced that it has appointed Julie Person as Senior Vice President, Human Resources.

Cyclacel Pharmaceuticals, Inc. announced the pricing of a public offering with expected total gross proceeds of approximately $20 million, before deducting placement agent fees and other offering expenses payable by the Company.